William Blair Issues Optimistic Forecast for TWST Earnings

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Investment analysts at William Blair lifted their Q1 2025 earnings per share (EPS) estimates for shares of Twist Bioscience in a report issued on Monday, November 18th. William Blair analyst M. Larew now expects that the company will earn ($0.58) per share for the quarter, up from their prior forecast of ($0.72). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.56) per share. William Blair also issued estimates for Twist Bioscience's Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.11) EPS.

TWST has been the subject of several other research reports. Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research note on Monday, August 5th. Scotiabank upped their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research report on Tuesday. Robert W. Baird upped their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research report on Tuesday. Finally, Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $51.78.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $41.11 on Thursday. The business has a 50 day simple moving average of $43.93 and a 200 day simple moving average of $46.15. Twist Bioscience has a 52 week low of $23.07 and a 52 week high of $60.90.

Insider Buying and Selling

In related news, SVP Paula Green sold 1,057 shares of the business's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92. Following the transaction, the senior vice president now owns 121,013 shares of the company's stock, valued at approximately $5,029,300.28. The trade was a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Dennis Cho sold 1,507 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the completion of the sale, the insider now directly owns 91,163 shares in the company, valued at $4,375,824. This trade represents a 1.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of TWST. Signaturefd LLC boosted its stake in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC acquired a new position in Twist Bioscience during the 2nd quarter worth about $43,000. Blue Trust Inc. lifted its position in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Twist Bioscience during the 2nd quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after buying an additional 381 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.